CCM
CSTL icon

Cadence Capital Management’s Castle Biosciences CSTL Stock Holding History

Cadence Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$538K Sell
10,450
-54,040
-84% -$2.4M 0.13% 127
2020
Q2 		$2.43M Buy
64,490
+2,699
+4% +$92.2K 0.35% 57
2020
Q1 		$1.84M Buy
+61,791
New +$1.86M 0.31% 73

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cadence Capital Management's CSTL Position: Q3 2020 in Review

Cadence Capital Management reduced its Castle Biosciences (CSTL) stake by 84% in Q3 2020, selling an estimated $2.4M and leaving 10,450 shares worth $538K. The position accounts for 0.13% of the portfolio, ranked #127.

Cadence Capital Management first reported a position in CSTL in Q1 2020 and has held it in 3 quarters since. The position peaked at $2.43M in Q2 2020. 144 funds tracked by Wall St. Rank hold CSTL as of Q3 2020.

  • Cadence Capital Management held 10,450 shares of Castle Biosciences worth $538K as of Q3 2020.
  • Cadence Capital Management sold 54,040 Castle Biosciences shares in Q3 2020, an estimated $2.4M.
  • Castle Biosciences made up 0.13% of Cadence Capital Management's portfolio in Q3 2020, its #127 holding.
  • Cadence Capital Management first reported a position in Castle Biosciences in Q1 2020 and has held it in 3 quarters since.
  • Cadence Capital Management's Castle Biosciences position peaked at $2.43M in Q2 2020.
  • 144 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.